Acta Oncologica最新文献

筛选
英文 中文
Diagnostic centres for non-specific symptoms of possible cancer: from service expansion to measurable patient benefit. 针对可能癌症的非特异性症状的诊断中心:从服务扩展到可衡量的患者受益。
IF 2.7 3区 医学
Acta Oncologica Pub Date : 2026-11-16 DOI: 10.2340/1651-226X.2026.46373
Peter Thye-Rønn, Søren Gray Worsøe Laursen, Brian D Nicholson, Willie Trevor Hamilton
{"title":"Diagnostic centres for non-specific symptoms of possible cancer: from service expansion to measurable patient benefit.","authors":"Peter Thye-Rønn, Søren Gray Worsøe Laursen, Brian D Nicholson, Willie Trevor Hamilton","doi":"10.2340/1651-226X.2026.46373","DOIUrl":"https://doi.org/10.2340/1651-226X.2026.46373","url":null,"abstract":"","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"884-887"},"PeriodicalIF":2.7,"publicationDate":"2026-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149416819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RET fusion-positive non-small cell lung cancer in Sweden: a nationwide registry study. 瑞典RET融合阳性非小细胞肺癌:一项全国性登记研究。
IF 2.7 3区 医学
Acta Oncologica Pub Date : 2026-10-29 DOI: 10.2340/1651-226X.2026.46817
Ella Äng Eklund, Hans Brunnström, Erik Lampa, Kerstin Gunnarsson, Anders Vikström, Johan Isaksson, Kristina Lamberg, Johan Botling, Henrik Fagman, Sama I Sayin, Gunnar Wagenius, Levent M Akyurek, Anders Berglund, Volkan I Sayin, Andreas Hallqvist
{"title":"RET fusion-positive non-small cell lung cancer in Sweden: a nationwide registry study.","authors":"Ella Äng Eklund, Hans Brunnström, Erik Lampa, Kerstin Gunnarsson, Anders Vikström, Johan Isaksson, Kristina Lamberg, Johan Botling, Henrik Fagman, Sama I Sayin, Gunnar Wagenius, Levent M Akyurek, Anders Berglund, Volkan I Sayin, Andreas Hallqvist","doi":"10.2340/1651-226X.2026.46817","DOIUrl":"10.2340/1651-226X.2026.46817","url":null,"abstract":"<p><strong>Background: </strong>Rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) is a rare but clinically meaningful molecular subgroup. RET inhibitors have demonstrated marked clinical activity; however, real-world data on disease characteristics and outcomes before their widespread introduction remain limited. This study characterizes clinical features, treatment patterns, and survival outcomes of RET fusion-positive NSCLC in a nationwide Swedish cohort, with other driver subgroups as descriptive comparisons.</p><p><strong>Methods: </strong>Patients ≥18 years diagnosed with histologically confirmed NSCLC in 2018-2022, registered in the Swedish National Lung Cancer Registry and with next-generation sequencing results available, were included. Individuals were categorized by oncogenic driver status, including RET, ALK, BRAF, EGFR, KRAS, ROS1, or wild type. Progression-free survival (PFS) and overall survival (OS) from diagnosis were estimated using Kaplan-Meier methods and standardized Cox proportional hazards models adjusted for age, sex, performance status, smoking, stage, and histology.</p><p><strong>Results: </strong>A total of 68 patients had RET fusion-positive NSCLC. The RET cohort was characterized by younger age, a high proportion of never-smokers (59%), and predominantly adenocarcinoma histology (96%). Most had stage IV disease at diagnosis and the highest rate of liver metastases (56%). KIF5B-RET (71%) and CCDC6-RET (19%) were the most frequent fusion partners. Adjusted median OS was 28 months (95% confidence interval [CI]: 13-46) for RET, 39 months (95% CI: 29-52) for ALK, and 17-26 months for the other groups, with overlapping CIs.</p><p><strong>Conclusion: </strong>RET fusion-positive patients were typically younger never-smokers with adenocarcinoma and had encouraging OS, despite limited access to selective RET inhibitors during the study period.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"875-883"},"PeriodicalIF":2.7,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13723043/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149294083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical factors associated with outcomes among patients receiving second-line therapy for advanced NSCLC. 晚期非小细胞肺癌患者接受二线治疗与预后相关的临床因素
IF 2.7 3区 医学
Acta Oncologica Pub Date : 2026-10-28 DOI: 10.2340/1651-226X.2026.46269
Vasileios Karagiannis, Levi Byskata, Nelli-Sofia Nåhls, Eero Sihvo, Antti Jekunen, Mikael Johansson, Heidi Andersén
{"title":"Clinical factors associated with outcomes among patients receiving second-line therapy for advanced NSCLC.","authors":"Vasileios Karagiannis, Levi Byskata, Nelli-Sofia Nåhls, Eero Sihvo, Antti Jekunen, Mikael Johansson, Heidi Andersén","doi":"10.2340/1651-226X.2026.46269","DOIUrl":"10.2340/1651-226X.2026.46269","url":null,"abstract":"","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"870-874"},"PeriodicalIF":2.7,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13723031/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149284552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Detection of circulating tumor HPV-DNA in patients with HPV-positive sinonasal and nasopharyngeal carcinoma. hpv阳性鼻窦癌和鼻咽癌循环肿瘤HPV-DNA的检测。
IF 2.7 3区 医学
Acta Oncologica Pub Date : 2026-10-20 DOI: 10.2340/1651-226X.2026.46393
Jakob Myllerup Jensen, Simone Kloch Bendtsen, Kathrine Kronberg Jakobsen, Katalin Kiss, Maria Rossing, Christian Grønhøj, Christian Von Buchwald
{"title":"Detection of circulating tumor HPV-DNA in patients with HPV-positive sinonasal and nasopharyngeal carcinoma.","authors":"Jakob Myllerup Jensen, Simone Kloch Bendtsen, Kathrine Kronberg Jakobsen, Katalin Kiss, Maria Rossing, Christian Grønhøj, Christian Von Buchwald","doi":"10.2340/1651-226X.2026.46393","DOIUrl":"10.2340/1651-226X.2026.46393","url":null,"abstract":"<p><strong>Background: </strong>Approximately 30% of sinonasal and nasopharyngeal carcinoma cases are HPV-associated, yet studies investigating circulating tumor HPV-DNA (ctHPV-DNA) among these patients are scarce. The aim of this study was to investigate the sensitivity of ctHPV-DNA in pretreatment blood samples from patients with HPV-positive (HPV+) sinonasal and nasopharyngeal carcinoma.</p><p><strong>Methods: </strong>Patients with a confirmed HPV+ sinonasal or nasopharyngeal carcinoma treated at the Department of Otorhinolaryngology, Head and Neck Surgery and Audiology at Rigshospitalet, Copenhagen, Denmark in the period 2017-2025 were included in this study. Blood samples were drawn in Streck tubes before treatment initiation and analysed for the presence of ctHPV-DNA by Droplet digital PCR (ddPCR).</p><p><strong>Results: </strong>Fifteen patients with primary HPV+ sinonasal or nasopharyngeal carcinoma were included. Except for two cases of HPV-related multiphenotypic carcinoma, all cases were squamous cell carcinoma. HPV16 was most prevalent and found in 6 patients (40%). HPV18 (n = 2), HPV33 (n = 1), HPV35 (n = 3), HPV45 (n = 1), and HPV56 (n = 2) were also represented. The sensitivity of detecting ctHPV-DNA in the pretreatment blood samples of the included patients was 80%. The level of ctHPV-DNA increased significantly with increasing T-category.</p><p><strong>Conclusion: </strong>ctHPV-DNA was detected in pretreatment blood samples in 80% of patients with HPV+ sinonasal and nasopharyngeal carcinoma. This supports further investigation of ctHPV-DNA as a biomarker for post-treatment surveillance in these patients.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"857-859"},"PeriodicalIF":2.7,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13688294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149223076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment attrition and outcomes of myeloma patients in Finland: a real-world study. 芬兰骨髓瘤患者的治疗损耗和预后:一项真实世界的研究。
IF 2.7 3区 医学
Acta Oncologica Pub Date : 2026-10-20 DOI: 10.2340/1651-226X.2026.46473
Mervi Putkonen, Katja Närhi, Johanna Vikkula, Riikka Mattila, Marika Waltari, Jonna Eeva, Anu Partanen
{"title":"Treatment attrition and outcomes of myeloma patients in Finland: a real-world study.","authors":"Mervi Putkonen, Katja Närhi, Johanna Vikkula, Riikka Mattila, Marika Waltari, Jonna Eeva, Anu Partanen","doi":"10.2340/1651-226X.2026.46473","DOIUrl":"10.2340/1651-226X.2026.46473","url":null,"abstract":"<p><strong>Background and purpose: </strong>Relapses, need for further treatment lines and significant treatment attrition are typical for multiple myeloma (MM). This retrospective study investigates attrition and outcomes among MM patients in Finland. Patient, material and methods: Study included all adult MM patients (n = 1733) diagnosed and treated in four hospital districts in Finland in 2013-2022. Data were collected from hospital data lakes, Statistics Finland and Social Insurance Institution. Treatment attrition was defined as death before next treatment line.</p><p><strong>Results: </strong>By the end of follow-up 31% of patients without stem cell transplantation (non-SCT) had died before initiation of second line treatment (2L), compared with 5% of stem-cell transplant (SCT) patients. The factors associating with this early attrition in the non-SCT cohort were older age (over 75 years), higher comorbidity burden, International Staging System (ISS), and (R)-ISS scores (p < 0.001). Furthermore, non-SCT patients were more likely administered less intensive therapy during 1L (p < 0.001). During the first 6 months post diagnosis in the non-SCT cohort, the most common immediate cause of death was MM. Also, during later stages MM was responsible for 54% of deaths in the non-SCT and 68% in the SCT cohorts whereas infections were linked principally with early deaths before 2L treatment.</p><p><strong>Interpretation: </strong>This study highlights significant treatment attrition across disease course and also early mortality especially in the non-SCT cohort resulting primarily from progressive MM or infections. The findings underscore the need for more tolerable and effective anti-myeloma treatments in earlier course of the disease to enhance patient survival.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"860-869"},"PeriodicalIF":2.7,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13688295/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149226892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Continuous intrathecal therapy for refractory cancer pain: A systematic review and meta-analysis focusing on partially implanted devices. 持续鞘内治疗难治性癌性疼痛:一项针对部分植入装置的系统回顾和荟萃分析。
IF 2.7 3区 医学
Acta Oncologica Pub Date : 2026-10-12 DOI: 10.2340/1651-226X.2026.45778
Mohammadhossein Radafshar, Maria Schelin, Elisabeth Bondesson, Sofia Löfvendahl, Eric Ahl, Sven Oredsson, Mikael Segerlantz
{"title":"Continuous intrathecal therapy for refractory cancer pain: A systematic review and meta-analysis focusing on partially implanted devices.","authors":"Mohammadhossein Radafshar, Maria Schelin, Elisabeth Bondesson, Sofia Löfvendahl, Eric Ahl, Sven Oredsson, Mikael Segerlantz","doi":"10.2340/1651-226X.2026.45778","DOIUrl":"10.2340/1651-226X.2026.45778","url":null,"abstract":"<p><strong>Context: </strong>Conventional pain therapies sometimes fail in patients with severe neuropathic pain or bone metastases. Intrathecal therapy provides an alternative but is resource-intensive, technically demanding and costly.</p><p><strong>Objective: </strong>To compare the advantages and limitations of partially implanted devices (PIDs) versus conventional medical management or totally implanted devices (TIDs) in adults with cancer-related pain.</p><p><strong>Methods: </strong>A systematic literature review up to September 2024 was conducted, with an updated search performed in August 2026. Eligible studies included those on adults with refractory cancer pain receiving PID intrathecal therapy compared with conventional therapy, and comparative studies evaluating PIDs versus TIDs. Pain intensity was analysed using a meta-analysis; a synthesis without meta-analysis was used for other outcomes.</p><p><strong>Results: </strong>Of the 1,102 records, 15 were included, evaluating pain intensity, systemic opioid dose, quality of life (QoL), depression/anxiety, functional capacity and complications in PID-treated patients. A meta-analysis of pain intensity at 4 weeks showed statistically significant reduction with intrathecal therapy, which also reduced opioid use and improved QoL. Complication rates were lower than in conventional therapy. Investigations of depression/anxiety and functional capacity were limited, with inconsistent findings. Certainty of evidence was moderate for pain intensity and QoL; low for opioid dose, depression/anxiety and complications; and very low for functional capacity.</p><p><strong>Conclusions: </strong>Intrathecal therapy for refractory cancer pain with PIDs provides superior pain relief and improved QoL compared with the conventional therapy in patients with refractory cancer pain. Evidence for psychological and functional outcomes remains limited. Overall certainty of evidence is low to moderate, but findings support intrathecal therapy as a clinically meaningful option for selected patients.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"845-856"},"PeriodicalIF":2.7,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13670362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Co-mutation patterns and survival associations in lung cancer: a comparative analysis of Swedish and global cohorts. 肺癌的共突变模式和生存关联:瑞典和全球队列的比较分析。
IF 2.7 3区 医学
Acta Oncologica Pub Date : 2026-10-09 DOI: 10.2340/1651-226X.2026.46330
Nicholas Karlowatz, Linda Köhn, Cedric Patthey, Jonas Nilsson, Mikael Johansson
{"title":"Co-mutation patterns and survival associations in lung cancer: a comparative analysis of Swedish and global cohorts.","authors":"Nicholas Karlowatz, Linda Köhn, Cedric Patthey, Jonas Nilsson, Mikael Johansson","doi":"10.2340/1651-226X.2026.46330","DOIUrl":"10.2340/1651-226X.2026.46330","url":null,"abstract":"<p><strong>Background and purpose: </strong>Co-occurring mutations in lung cancer can influence disease progression and treatment response. Understanding these patterns may refine prognostic stratification and therapeutic decisions.</p><p><strong>Patients/materials and methods: </strong>We analysed targeted sequencing data from 528 North Swedish non-small cell lung cancer (NSCLC) patients, validating findings in 2,239 global patients. Co-mutation enrichment was assessed using the Fisher's exact test with odds ratios, and survival associations were evaluated using Kaplan-Meier/log-rank analyses and Cox models.</p><p><strong>Results: </strong>The North Sweden cohort showed non-random co-mutation patterns shaped by pathway dependencies. The combination of Kirsten rat sarcoma virus oncogene homolog (KRAS) and STK11 co-mutation was significantly enriched in both North Sweden (p = 4.7 × 10-4) and globally (p = 2.5 × 10-22), with North Sweden co-mutants showing significantly worse survival compared with KRAS-only cases (p = 0.037). Epidermal growth factor receptor (EGFR)+phosphate and tensin homolog (PTEN) co-mutation was significantly associated with poorer survival in both cohorts (North Sweden: p = 0.013; World: p = 0.0013). EGFR+TP53 co-mutation trended towards poorer survival compared with EGFR alone, reaching significance globally (p = 1.4 × 10-5). Adenomatous polyposis coli (APC) and PTEN were positively enriched in North Sweden (p = 0.018), and co-mutants had worse survival than APC-only cases (p = 0.029), a pattern mirrored globally. KRAS+TP53 was a frequent co-mutation but not prognostically significant. KRAS and EGFR were strongly mutually exclusive in both cohorts.</p><p><strong>Interpretation: </strong>Pathway-level co-mutation interactions, rather than individual mutation burden, drive survival heterogeneity in lung cancer. Specific co-mutations, such as KRAS+STK11 and APC+PTEN, are enriched and linked to worse survival, supporting the clinical relevance of co-mutation analysis in NSCLC.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"836-844"},"PeriodicalIF":2.7,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13660355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149134835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tools for providing information to patients about high-tech medical resources for treatment of cancer. 向患者提供有关治疗癌症的高科技医疗资源信息的工具。
IF 2.7 3区 医学
Acta Oncologica Pub Date : 2026-10-02 DOI: 10.2340/1651-226X.2026.45529
Julie Gehl, Tatiana Michel, Erik Rokkones, Soleakhena Ken, Gregor Sersa, Irene Torres-Espallardo, Ester Orlandi, Laura Ridolfi, Nina Schmidt, Ingrid Kruecken, Barbara Leonardi, Margareta Haag, Aurélie Garcin, Anne-Laure Giraudet, Sandrine Lavallé, Colin Patrick Cantwell, Alexander Jorge Cortez, Chiara Marazzi, Roger Olofsson Bagge, Massimiliano Petrini, Francesca Bonifazi, Vincent Bourbonne, Frédéric Courbon, Ibrahim Edhemović, Lisa Licitra, Sergio Roman-Roman, Jean-Yves Blay
{"title":"Tools for providing information to patients about high-tech medical resources for treatment of cancer.","authors":"Julie Gehl, Tatiana Michel, Erik Rokkones, Soleakhena Ken, Gregor Sersa, Irene Torres-Espallardo, Ester Orlandi, Laura Ridolfi, Nina Schmidt, Ingrid Kruecken, Barbara Leonardi, Margareta Haag, Aurélie Garcin, Anne-Laure Giraudet, Sandrine Lavallé, Colin Patrick Cantwell, Alexander Jorge Cortez, Chiara Marazzi, Roger Olofsson Bagge, Massimiliano Petrini, Francesca Bonifazi, Vincent Bourbonne, Frédéric Courbon, Ibrahim Edhemović, Lisa Licitra, Sergio Roman-Roman, Jean-Yves Blay","doi":"10.2340/1651-226X.2026.45529","DOIUrl":"https://doi.org/10.2340/1651-226X.2026.45529","url":null,"abstract":"<p><strong>Background and purpose: </strong>High-tech medical resources play an increasingly important role in cancer diagnosis and treatment. However, accessing information about these technologies remains challenging due to their complexity and a lack of clear information pathways to obtain reliable information. This, in turn, contributes to inequalities in healthcare. Patient/material and methods: The Joint Action Network of Expertise on Cancer (JANE-2) is one of the largest networks under Europe's Beating Cancer Plan. In JANE-2, the work package on High-Tech Medical Resources comprises seven domains of rapidly evolving technologies, namely Nuclear Medicine, Radiomics, Innovative Radiotherapy, Innovative Surgery, Physical Methods of Ablation, Cell Therapies, and Ex-vivo Testing of Agents. Leaders from these domains, together with patient representatives, have authored a review of the challenges of providing patients with information about high-tech medical resources, and have proposed potential solutions.</p><p><strong>Results: </strong>This article describes the challenges associated with providing adequate information to patients, the resulting consequences, and potential solutions. The article also specifically describes technologies related to the seven high-tech domains that are central to cancer treatment. Patient information tools related to these technologies are provided as supplementary material to the article.</p><p><strong>Interpretation: </strong>Cancer diagnosis and treatment are not only becoming increasingly effective but also more complex with the adoption of novel technologies. This article discusses the challenges and potential solutions related to the availability of patient information and provides examples of patient information tools for seven key and rapidly advancing technologies.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"818-835"},"PeriodicalIF":2.7,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13635841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149102529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeted ALK inhibition achieving tumour control in metastatic melanoma: a case report. 靶向ALK抑制在转移性黑色素瘤中实现肿瘤控制:一例报告。
IF 2.7 3区 医学
Acta Oncologica Pub Date : 2026-10-01 DOI: 10.2340/1651-226X.2026.46424
Cornelia Schuster, Irja Alida Oppedal, Liv Iren Vinnem, Eirin Lunden Abrahamsson, Torill Myklestad Barrett, Eli Sihn Samdal Steinskog, Hege Elisabeth Giercksky Russnes, Åslaug Helland
{"title":"Targeted ALK inhibition achieving tumour control in metastatic melanoma: a case report.","authors":"Cornelia Schuster, Irja Alida Oppedal, Liv Iren Vinnem, Eirin Lunden Abrahamsson, Torill Myklestad Barrett, Eli Sihn Samdal Steinskog, Hege Elisabeth Giercksky Russnes, Åslaug Helland","doi":"10.2340/1651-226X.2026.46424","DOIUrl":"https://doi.org/10.2340/1651-226X.2026.46424","url":null,"abstract":"","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"814-817"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13635839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149102604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary treatment and relative survival by stage and age in vaginal carcinoma: a population-based SweGCG study. 阴道癌分期和年龄的初始治疗和相对生存率:一项基于人群的SweGCG研究。
IF 2.7 3区 医学
Acta Oncologica Pub Date : 2026-09-30 DOI: 10.2340/1651-226X.2026.45598
Kristina Hellman, Maria Bjurberg, Christer Borgfeldt, Pernilla Dahm Kähler, Angelique Flöter Rådestad, Jenny-Maria Jönsson, Preben Kjølhede, Cecilia Olsson, Camilla Sköld, Katja Stenström Bohlin, Karin Stålberg, Erik Holmberg, Elisabeth Åvall Lundqvist
{"title":"Primary treatment and relative survival by stage and age in vaginal carcinoma: a population-based SweGCG study.","authors":"Kristina Hellman, Maria Bjurberg, Christer Borgfeldt, Pernilla Dahm Kähler, Angelique Flöter Rådestad, Jenny-Maria Jönsson, Preben Kjølhede, Cecilia Olsson, Camilla Sköld, Katja Stenström Bohlin, Karin Stålberg, Erik Holmberg, Elisabeth Åvall Lundqvist","doi":"10.2340/1651-226X.2026.45598","DOIUrl":"10.2340/1651-226X.2026.45598","url":null,"abstract":"<p><strong>Background and purpose: </strong>This study aimed to investigate treatment patterns and survival outcomes in population-based data describing treatment and survival of primary vaginal carcinoma (VC) in a routine clinical setting, stratified by age group and stage.</p><p><strong>Methods: </strong>This nationwide, population-based study included women diagnosed with epithelial VC between 2011 and 2020, registered in the Swedish Quality Register for Gynecologic Cancer. Five-year relative survival (RS) was estimated using the Pohar Perme method. The excess mortality rate ratio (EMRR) was assessed by Poisson regression.</p><p><strong>Results: </strong>In total, 252 women were identified, 29% were aged ≥ 80 years. The median follow-up time was 7.5 years. The most common stages were I and II (26% each). Definitive radiotherapy, with or without chemotherapy, was administered to 59% of patients. Among women with stage I, 48% underwent primary surgery and 29% received adjuvant radiotherapy. Treatment patterns differed across age groups. Among women aged ≥ 80 years, staging was omitted in 18%, and in stage I disease 25% received palliative therapy. None of the irradiated women aged ≥ 80 years received chemoradiotherapy, compared to all women aged 20-59 years. The overall 5-year RS for stages I-IV was 51% (95% confidence interval [CI] 43-58). In stages I-II, the 5-year RS was 28% among women aged ≥80 years and 84% among those aged < 60 years (EMRR of 5.2; 95% CI 1.7-15.6).</p><p><strong>Interpretation: </strong>Primary treatment of vaginal cancer in Sweden generally followed international guidelines, except among women aged ≥ 80 years. The markedly poorer RS in this age group suggests both diagnostic and therapeutic compromises.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"805-813"},"PeriodicalIF":2.7,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13635840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书